CA184043_4 | R Documentation |
Kaplan-Meier digitized data from CA184043, figure 4 (PMID 24831977). A reported sample size of 799 for a primary endpoint of OS in prostate cancer.
CA184043_4
A data frame of 799 observations and 3 variables:
time | event time (in months) | |
event | PFS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (ipilimumab, placebo) | |
Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014; 15: 700–12.
summary(CA184043_4)
kmplot(CA184043_4)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.